5 European Projects Found
Searched on 125080 European Projects
FINISHED
Clinical proof of concept through a randomised phase II study: a combination of immunotherapy and stereotactic ablative radiotherapy as a curative treatment for limited metastatic lung cancer (IMMUNOSABR)
Start date: Jan 1, 2017, End date: Dec 31, 2022,
IMMUNOSABR is geared towards opening up a new paradigm in treating metastatic cancer by obtaining clinical proof of concept for a novel bi-modal curative treatment strategy. High precision stereotactic ablative radiotherapy (SABR) is combined with immunotherapy to form a powerful synergistic anti-tumour strategy. The approach relies on the direct cytotoxic effect of SABR, the abscopal effect of ra ...
Read Project
17
Partners Participants
FINISHED
Advanced T-cell Engineered for Cancer Therapy (ATECT)
Start date: Dec 1, 2013, End date: Nov 30, 2018,
"T-cell engineering strategies for Cancer therapy, either Chimeric Antigen Receptors (CARs) or TCR transfer holds promise to revolutionize cancer treatment. There are, however, considerable barriers to be overcome to take this form of therapy to a format that can benefit all EU citizens with a wide range of common cancers. The aim of this consortium is to exploit advances in T-cell engineering to ...
Read Project
6
Partners Participants
FINISHED
European Consortium for High-Throughput Research in Rare Kidney Diseases (EURENOMICS)
Start date: Oct 1, 2012, End date: Sep 30, 2017,
EURenOmics will integrate several established consortia devoted to rare kidney diseases with eminent need and potential for diagnostic and therapeutic progress (i.e. steroid resistant nephrotic syndrome, membranous nephropathy, tubulopathies, complement disorders such a haemolytic uraemic syndrome, and congenital kidney malformations). The Consortium has access to the largest clinical cohorts asse ...
Read Project
29
Partners Participants
FINISHED
IMmune MOdulating strategies for treatment of MErkel cell Carcinoma (IMMOMEC)
Start date: Jan 1, 2012, End date: Dec 31, 2016,
"Merkel cell carcinoma (MCC) is a highly aggressive, often lethal neuroendocrine cancer of the skin associated with the recently discovered, common Merkel cell polyomavirus (MCV). With an incidence of 0.44 per 100,000 MCC is a very rare cancer. Notably, however, although MCC is 40 times less common than malignant melanoma, MCC has a dramatically higher mortality rate than melanoma rendering MCC to ...
Read Project
11
Partners Participants
FINISHED
Profiling Responders In Antibody Therapies (PRIAT)
Start date: Nov 1, 2012, End date: Oct 31, 2014,
...ce being pioneers in the field of therapeutic antibody development and (pre-) clinical studies and will tackle both of these challenges:Innovative immunocytokines L19-IL2 and F8-IL10 are developed by Philogen for the treatment of metastatic melanoma and rheumatoid arthritis respectively at multiple clinical centres including Graz and Tübingen.Building on the strong background in proteomics biomark ...
Read Project
